Valued with a market capitalization of $50.3 billion, Becton, Dickinson and Company (BDX) is a global medical technology leader headquartered in Franklin Lakes, New Jersey. It develops, manufactures and sells a wide range of medical supplies, devices and interventional solutions.
Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and BDX fits the label perfectly, as its market capitalization exceeds this threshold, underscoring its size, influence, and dominance within the medical instruments and supplies industry. By prioritizing innovation in high-growth fields such as biologic drug delivery, automated medication management and advanced patient monitoring, the company continues to advance the world of healthcare by improving clinical outcomes and operational efficiency for providers and patients.
This healthcare giant is currently trading 5.8% below its 52-week high of $187.35, reached on February 24. BDX stock has risen 15.8% over the past three months, significantly outpacing the 3.3% gain of the Dow Jones Industrial Average ($DOWI) over the same time period.
Additionally, on a year-over-year basis, BDX stock is up 15.7%, compared to the DOWI’s 1.9% gain. However, over the past 52 weeks, BDX has gained marginally, lagging DOWI’s 13.3% rally.
Confirming its bullish trend, BDX has been trading above its 200-day moving average since late November, with slight fluctuations, and remains above its 50-day moving average since mid-November.
On February 9, BDX stock plunged 1.3% despite reporting better-than-expected fourth-quarter results. The company’s revenue rose 1.6% year over year to $5.3 billion, beating consensus estimates. However, its management remains cautious amid persistent macroeconomic and regulatory headwinds, especially from China and vaccine demand, which could have made investors nervous. Additionally, its adjusted EPS of $2.91 handily beat analyst expectations of $2.82.
BDX has notably outperformed its rival, Intuitive Surgical, Inc. (ISRG), which fell 10.7% over the past 52 weeks and 11.1% year over year.
Given BDX’s recent outperformance, analysts remain cautiously optimistic about its prospects. The stock has a “Moderate Buy” consensus rating from the 14 analysts covering it, and the average price target of $194.08 suggests a 10% premium to its current price levels.
On the date of publication, Neharika Jain had no (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com